Top 50 Life Science VC (Venture Capital) Funds in February 2025

Investor	Life Science investments
SOSV	51
ARCH Venture Partners	28
Sofinnova Partners	24
Alexandria Venture Investments	22
Northpond Ventures	20
Parkwalk Advisors	18
Novartis Venture Fund	17
RA Capital Management	16
OrbiMed	16
Google Ventures	16
UK Innovation & Science Seed Fund	15
Fifty Years	15
Oxford Science Enterprises	15
Atlas Venture	14
Versant Ventures	14
SR One	14
Third Rock Ventures	13
Bpifrance	13
DCVC	13
Prox Ventures	12
Civilization Ventures	12
5AM Ventures	11
Hatteras Venture Partners	11
Lux Capital	11
Roche Venture Fund	11
8VC	11
M Ventures	11
MPM Capital	11
Horizons Ventures	11
Kurma Partners	11
Andreessen Horowitz	10
Alix Ventures	10
KdT Ventures	10
Dementia Discovery Fund	10
Takeda Ventures	10
Novo Holdings	10
Khosla Ventures	10
Sahsen Ventures	10
JDRF T1D Fund	9
Artis Ventures	9
HTGF \| High-Tech Gruenderfonds	9
Forbion Capital Partners	9
Rev1 Ventures	9
Oxford Science Enterprises	9
Cormorant Asset Management	9
F-Prime Capital	9
Omega Funds	9
Vivo Capital	9
New Enterprise Associates	9
Longwood Fund	9

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, United Kingdom

Portfolio highlights

Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
Kardigan — Kardigan is building the heart health company of the future focused on developing medicines to make cardiovascular disease curable, preventable, and no longer the leading cause of death.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
Berry Street — Nutrition therapy by registered dietitians covered by insurance.

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Canada, France

Portfolio highlights

Meiogenix — Meiogenix is a biotech company developing breeding technologies to unlock the unexplored genetic diversity of organisms. Meiogenix expands the natural biodiversity and helps developing new products to address global food and industrial challenges.
nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
Nuvig Therapeutics — Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inﬂammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmunediseases.

Northpond Ventures is a science-driven venture capital ﬁrm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and aﬃliated industries.

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
VieCure — The VieCure platform is an Clinical Decision Support solution in Oncology that combines the power of artificial intelligence, codified clinical rules and pathways, precision oncology, telehealth, smartphone technology, and the EMR to transform cancer care.
Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
illumion — Illumion develops high-throughput optical tools to accelerate battery material development

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Alesta Therapeutics — Alesta Therapeutics pioneers innovative small molecule therapies for rare diseases, including hypophosphatasia and Charcot-Marie-Tooth

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
United States, United Kingdom, Canada

Portfolio highlights

Verdiva Bio — Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Vor Biopharma — Shield the healthy cells, expose the cancer - Vor Bio (also known as Vor Biopharma) aims to cure blood cancers through cell and genome engineering.

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

Aerin Medical — Aerin Medical offers VivAer for nasal airway obstruction treatment and RhinAer for chronic runny nose treatment. Lasting relief when other solutions fall short.
Stairway Medical — Stairway Medical is a developer of implantable brain-computer interface technology.
Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.

GV supports innovative founders moving the world forward.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Allara — Allara is your all-in-one virtual care team for hormonal, metabolic & gynecological conditions such as PCOS and Endometriosis.
Synthesia — Create AI videos by simply typing in text. Make engaging videos for e-learning, customer onboarding, etc. No need for actors, cameras or audio equipment.
comstruct — comstruct is working on a platform that will allow construction companies to digitize and automate material purchasing. All delivery bills, invoices, and purchase orders, as well as processes such as invoice verification, can be exchanged digitally with suppliers. All data pertaining to the purchasing process is made available for documentation,evaluation, and process optimization.

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Antiverse — Designing biologics for 100 challenging targets
iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

WE BACK HEROES using technology to solve the world's biggest problems

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Germany, Canada

Portfolio highlights

Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
Waypoint Bio — Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United Kingdom, United States, Finland

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
Light Horse Therapeutics — Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
Kala Pharmaceuticals — Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Marea Therapeutics — Marea Therapeutics is a clinical-stage biotechnology firm that uses the most recent advancements in human genetics to create first-in-class, next-generation medications for cardiometabolic illnesses.
Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Investment focus

Software, Information Technology, Health Care
Seed, Funding Round, Series A
France, United States, Switzerland

Portfolio highlights

Swan — Use Swan's APIs to embed white-labeled banking features like accounts, cards, and IBANs into your workflows and UX.
CROWN — CROWN is modernizing procurement negotiations through ethical eAuctions.
Keey Aerogel — Home - Welcome to the homepage of KEEY Aerogel ! Discover our company, our products and our know-how in aerogels.

We are deep tech venture capital.

Investment focus

Software, Artificial Intelligence, Health Care
Seed, Series A, Series B
United States, Canada, United Kingdom

Portfolio highlights

Fervo Energy — Fervo Energy delivers 24/7 carbon-free energy through development of next-generation geothermal projects.
Slip Robotics — Auto-load and auto-unload any truck in 5 minutes with SlipBots to drive 10X speed, safety, and savings across the supply chain. With Slip, truckers don't wait and forklift drivers don't risk it.
Alta Resource Technologies — Alta Resource Technologies is on a mission to reinvent mining by harnessing advanced biochemistry to cost-effectively source the critical raw materials needed to power next-generation technology and bolster economic security. Our groundbreaking technology platform leverages customizable proteins to separate high-purity rare earth elements and otheressential minerals with unprecedented selectivity while dramatically reducing the environmental impact of mining.

Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.

Investment focus

Medical, Biotechnology, Health Care
Seed, Funding Round, Series A
China, United States, United Kingdom

Portfolio highlights

Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
Cytonus Therapeutics — Cytonus Therapeutics is a biotech company that develops a therapeutic platform designed to treat immune-related disorders. The Cargocyte platform at Cytonus has diverse applications as it can be engineered to target specific tissues and can deliver strategic therapeutic payloads.
Rapafusyn Pharmaceuticals — Rapafuysn is pioneering RapaGlues - a modality of non-degrading molecular glues that addresses hard-to-drug targets.

DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, United Kingdom, Brazil

Portfolio highlights

SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Integrated Biosciences — Integrated Biosciences is the first company in history to be able to virtually stress cells.

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

RareCyte — Rarecyte provides precision medicine solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics.
TMRW Life Sciences — TMRW helps patients and clinics safely store their eggs and embryos
Tectonic Therapeutic — Tectonic and AVROBIO have completed their anticipated merger.Please follow this link to our press release for additional information.

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
United States, Canada

Portfolio highlights

Endogenex — DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
Synaptrix — Synaptrix is a medical device start-up company dedicated to developing and commercializing drug-free pain management solutions for postoperative joint surgery patients. The proprietary NOVABLOC system is a procedure-based solution that delivers a novel type of electrical stimulation. Human feasibili
AtaCor Medical — AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Investment focus

Software, Health Care, Biotechnology
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Lanai — The AI Empowerment Platform - Help your team achieve the extraordinary in the age of AI.
Fiddler AI — Monitor, observe, analyze, and explain your machine learning models in production with Fiddler AI. Maximize ML model performance with our Model Performance Management Platform that simply plugs in.
Bluenote Health — Accelerate innovation with AI built for and trusted by leading life sciences companies.

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team Latest News See more Our Work OUR APPROACH ABOUT DIABETES
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.

Investment focus

Software, Health Care, Artificial Intelligence
Seed, Series A, Series B
United States, Canada, United Kingdom

Portfolio highlights

Coram AI — Secure your business with cloud based security cameras from Coram AI. Remotely monitor your property with advanced AI security cloud camera systems. Book a demo.
Overland AI — Overland AI is a manufacturer and developer of autonomous navigation for off-road autonomous vehicles.
Ember Software — Simplify fire inspections with Ember Software. Access customizable NFPA and state-compliant forms, centralized data, AHJ submissions, and smart proposals.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
NovoLINC — NovoLINC is a pioneering startup that provides thermal interface solutions. It develops a distinctive system of nanostructured materials and a proprietary manufacturing process with the objective of transforming thermal management.
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.

Powering Breakthroughs in Life Sciences

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series A, Series C
United States, United Kingdom, Canada

Portfolio highlights

Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies

Investing in the deep science and technology that can propel humanity towards a radically better future.

Investment focus

Biotechnology, Artificial Intelligence, Software
Series A, Series B, Seed
United States, United Kingdom, Canada

Portfolio highlights

Notpla — We are a combination of designers and chemists, engineers and entrepreneurs. We’re hard to define because what we’re doing hasn’t been done before. We create advanced packaging solutions that disappear, naturally.
Owlstone Medical — Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease, and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novelnon-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA Breath Sampler ensures a reliable collection of breath samples. The volatile organic compounds (VOCs) present in the breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by the therapeutic response. The company also Breath Biopsy products and services to academic, clinical, and pharma partners who want to develop breath-based diagnostics for their own applications.
Fleet Space Technologies — Fleet is an agile, next generation connectivity company. Our mission is to Connect Everything using cutting-edge communications and space technologies to maximise the resource efficiency of human civilisation and enable the next industrial revolution with our free, ubiquitous connectivity platform.

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Series A, Seed, Series B
France, Switzerland, Spain

Portfolio highlights

Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Omnidoc — Omnidoc is a tele-expertise platform for healthcare professionals to exchange medical opinions.
Hopia — Hopia is a scheduling solution that optimizes human and material resources for healthcare institutions. Hopia centralizes the management of doctors' and nurses' schedules and uses constrained optimization and prediction algorithms to propose the most optimal organization for all stakeholders.

Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.

Investment focus

Software, Information Technology, Internet
Series A, Seed, Series B
United States, United Kingdom, Brazil

Portfolio highlights

ElevenLabs — Create the most realistic speech with our AI audio tools in 1000s of voices and 32 languages. Easy to use API's and SDK's. Scalable, secure, and customizable voice solutions tailored for enterprise needs. Pioneering research in Text to Speech and AI Voice Generation.
Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
Echo Neurotechnologies — Echo Neurotechnologies specializes in brain-machine interfaces, which provide patients control over external devices. The company creates neuroscience products that aim to improve people's lives.

Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....

Investment focus

Biotechnology, Health Care, Life Science
Seed, Series A, Pre-Seed
United States

Portfolio highlights

Xilis — Xilis is an oncology and precision health company that diagnoses cancer and finds the right treatment. The company uses “micro-organoids” to make thousands of 3D replicas of a patient’s tumor in about six days, which the company says can be used for testing for drug compatibility faster. It was founded in 2019 and is headquartered in Durham,North Carolina.
Elegen — Elegen is powering the bioeconomy with high-accuracy DNA synthesis that delivers industry-leading speed, length, and quality.
Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.

KdT Ventures is the standard for early-stage frontier science investing.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Israel, Germany

Portfolio highlights

Shiprocket — Shiprocket is India's most-used eCommerce logistics and shipping software solution for the best courier services. Avail features like COD (Cash on Delivery), prepaid delivery, automated shipping, etc.
March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases

SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Sudo Biosciences — Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class.
LOQUS23 THERAPEUTICS — LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases

Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Numab — Numab Therapeutics AG
Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.

Khosla Ventures invests in companies that are bold, early, and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs.Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech, digital health, medtech anddiagnostics, therapeutics, and frontier technology.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Series B, Seed
United States, India, United Kingdom

Portfolio highlights

Jones — Jones is a software company that rebuilt liability management for real estate companies who want do less and get more – much more. We are solving one of the most archaic and outdated processes in commercial real estate - insurance certificates. For owners, managers and developers who need to solve insurance compliance for everyone in the valuechain, Jones is the simplest solution ever made.
Basis — Basis operates as an AI platform built specifically for accounting firms.
Clear Labs — Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics, and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity.Clear Labs’ turnkeyplatform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track, and mitigate tomorrow’s novel pathogens.

Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.

Investment focus

Biotechnology, Health Care, Non Profit
Funding Round, Series A, Seed
United States, China, Ghana

Portfolio highlights

Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Funding Round, Series B
United States, France, Italy

Portfolio highlights

vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
Eledon Pharmaceuticals — Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
Cour Pharmaceuticals Development — COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance...

Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.

Investment focus

Health Care, Biotechnology, Software
Series A, Series B, Seed
United States, India, Germany

Portfolio highlights

Network Bio — Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools.
Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Pagent — Pagent develops AI systems.
AUDAVIS — AUDAVIS is developing the most innovative approach that will revolutionize auditing. With data-driven full automation by AUDAVIS and a new AI-based approach, every financial statement becomes a breeze with unprecedented efficiency.
Lindis Blood Care — Lindis Blood Care´s mission is to optimise the outcome of cancer surgeries by developing a Medical Device to remove cancer cells from blood during cancer surgeries to enable Autologous Blood Transfusion.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Numab — Numab Therapeutics AG
Verdiva Bio — Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!

Investment focus

Software, Health Care, Information Technology
Seed, Series A, Funding Round
United States, Germany

Portfolio highlights

Myoptechs — Myoptechs, a pediatric ophthalmic medical device startup in the clinical stage, has made advancements in its fund-raising and clinical research program. The company creates innovative soft contact lenses and spectacles that reduce the growth of myopia while offering incredibly clear vision.
Nichefire — Nichefire is an AI-power marketing analytics company.
STAQ Pharma — STAQ Pharma offers safety, transparency, availability, and quality to compounded medications. It features Onsite production of non-sterile to sterile solutions. And sterile-to-sterile repackaging. Inventory systems to forecast needs and proactively provide partners with critical products.It was founded in 2018 and headquartered in Denver,Colorado.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Switzerland

Portfolio highlights

Numab — Numab Therapeutics AG
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
Kala Pharmaceuticals — Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.

F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, United Kingdom, China

Portfolio highlights

Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
Eleos Health — Automate documentation, alleviate provider burnout, and elevate care quality with the CareOps Automation platform from Eleos Health.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Alleviant Medical — Interventional therapy for congestive heart failure
Aviceda Therapeutics — Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination ofcutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively.

The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series C, Post-IPO Equity
United States, China, United Kingdom

Portfolio highlights

35Pharma — 35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.
Trevi Therapeutics — Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Chentai New Materials — Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series B, Series A, Series C
United States, India, China

Portfolio highlights

Music AI — State-of-the-art ethical AI solutions for audio and music applications. The highest quality audio separation available.
Instabase — Instabase combines the latest AI breakthroughs with industry expertise to create real business value for your business.
ElevenLabs — Create the most realistic speech with our AI audio tools in 1000s of voices and 32 languages. Easy to use API's and SDK's. Scalable, secure, and customizable voice solutions tailored for enterprise needs. Pioneering research in Text to Speech and AI Voice Generation.

Longwood creates and invests in science-based companies that develop novel solutions for important medical problems

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Series B, Series C
United States, United Kingdom, Italy

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.